News

ADIAL PHARMACEUTICALS RECEIVES NOTICE OF ALLOWANCE ON U.S. PATENT FOR THE TREATMENT FOR OPIOID USE DISORDER USING AD04

CHARLOTTESVILLE, Va., (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the U.S. Patent and Trademark Office (USPTO) has mailed a Notice of Allowance for US Patent Application No. 16/784,051, a patent application for the treatment for opioid use disorder (OUD) using AD04. This patent application covers treatment of patients with a specific genetic biomarker for the serotonin-3 receptor.

AD04 is currently being evaluated in the Company’s ONWARD trial, which is designed as a Phase 3 clinical study to evaluate the efficacy, safety and tolerability of AD04 in patients with alcohol use disorder (AUD). The Company believes AD04 may also hold significant potential for the treatment of OUD since the physiology and neurotransmitters involved in opioid addiction are similar to alcohol and could be expected to be modulated by a serotonin-3 receptor antagonist.

William Stilley, Adial’s Chief Executive Officer, stated, “We continue to build the patent estate around AD04, and, including expected extensions, we believe AD04 will have robust, long-term patent protection of our intellectual property through 2036. Specifically, this represents our ninth U.S. patent, in addition to numerous international patents, covering AUD, OUD, or both. OUD remains a significant, yet underserved market. According to the CDC’s National Center for Health Statistics, there were an estimated 93,000 drug overdose deaths in the United States alone during 2020, an increase of nearly 30% from the prior year. The Centers for Disease Control and Prevention estimates that the total economic burden of prescription opioid misuse alone in the United States is $78.5 billion a year, including the costs of healthcare, lost productivity, addiction treatment, and criminal justice involvement.”

A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patent would have a term that expires no earlier than July 1, 2031.

Read more here.

Recent News

02/05/2025

Project Vital bringing millions in funding to Roanoke-Blacksburg’s life sciences

The Roanoke-Blacksburg region is establishing itself as a biomedical research hub and medical device innovation center. About $5 million from the state could help move that work from labs to markets. Those millions will fund Project Vital: Virginia Innovations and Technology Advancements in Life Sciences. It’s a collaboration among the Roanoke-Blacksburg Innovation Alliance (formerly Verge),

01/31/2025

AGC Pharma Chemicals announces expansion of HPAPI capabilities in Barcelona

AGC Pharma Chemicals, a leading innovator in pharmaceutical manufacturing with over 40 years of expertise in Contract Development Manufacturing Operations (CDMO) for small molecule APIs based in Barcelona (Spain) and Japan, announces a significant expansion of its High Potency Active Pharmaceutical Ingredients (HPAPI) capabilities, enabling seamless scale-up from grams to tons within a single integrated

01/30/2025

OrthoPreserve Receives Both FDA Breakthrough Device Designation and Prestigious TAP Enrollment for Meniscus Implant to Revolutionize Knee Pain Treatment

OrthoPreserve, a company developing orthopedic implant solutions, announced today it has been granted both a Breakthrough Device Designation and Total Product Life Cycle Advisory Program (TAP) enrollment from the U.S. Food & Drug Administration (FDA) for Defender, a meniscus replacement implant. The designation covers the use of the therapeutic medical device to treat patients who